Regulation of angiogenesis and vascular permeability by src family kinases: Opportunities for therapeutic treatment of solid tumors

Serk In Park; Ami N. Shah; Jing Zhang; Gary E. Gallick

doi:10.1517/14728222.11.9.1207

Regulation of angiogenesis and vascular permeability by src family kinases: Opportunities for therapeutic treatment of solid tumors

Serk In Park
, Ami N. Shah
, Jing Zhang
, Gary E. Gallick^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

60 Citations (Scopus)

Abstract

Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

Original language	English
Pages (from-to)	1207-1217
Number of pages	11
Journal	Expert Opinion on Therapeutic Targets
Volume	11
Issue number	9
DOIs	https://doi.org/10.1517/14728222.11.9.1207
Publication status	Published - 2007 Sept
Externally published	Yes

Bibliographical note

Funding Information:
National Cancer Institute grant CA-16672 (GE Gallick), Lockton Foundation (GE Gallick), Gillson Longenbaugh Foundation (GE Gallick), National Institutes of Health T32 CA-09599 (AN Shah), the Eleanor B. Pillsbury Fellowship-University of Illinois Hospital (AN Shah) and the Sowell-Huggins Fellowship (J Zhang). GE Gallick is the Sowell-Huggins Professor of Cancer Biology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Angiogenesis
Metastasis
Protein tyrosine kinase
Src family kinase
Tumor progression
Tyrosine kinase inhibitors
VEGF
Vascular permeability

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1517/14728222.11.9.1207

Cite this

@article{180dcd2de1c340fbaab15d784c685826,

title = "Regulation of angiogenesis and vascular permeability by src family kinases: Opportunities for therapeutic treatment of solid tumors",

abstract = "Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.",

keywords = "Angiogenesis, Metastasis, Protein tyrosine kinase, Src family kinase, Tumor progression, Tyrosine kinase inhibitors, VEGF, Vascular permeability",

author = "Park, \{Serk In\} and Shah, \{Ami N.\} and Jing Zhang and Gallick, \{Gary E.\}",

note = "Funding Information: National Cancer Institute grant CA-16672 (GE Gallick), Lockton Foundation (GE Gallick), Gillson Longenbaugh Foundation (GE Gallick), National Institutes of Health T32 CA-09599 (AN Shah), the Eleanor B. Pillsbury Fellowship-University of Illinois Hospital (AN Shah) and the Sowell-Huggins Fellowship (J Zhang). GE Gallick is the Sowell-Huggins Professor of Cancer Biology.",

year = "2007",

month = sep,

doi = "10.1517/14728222.11.9.1207",

language = "English",

volume = "11",

pages = "1207--1217",

journal = "Expert Opinion on Therapeutic Targets",

issn = "1472-8222",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Regulation of angiogenesis and vascular permeability by src family kinases

T2 - Opportunities for therapeutic treatment of solid tumors

AU - Park, Serk In

AU - Shah, Ami N.

AU - Zhang, Jing

AU - Gallick, Gary E.

N1 - Funding Information: National Cancer Institute grant CA-16672 (GE Gallick), Lockton Foundation (GE Gallick), Gillson Longenbaugh Foundation (GE Gallick), National Institutes of Health T32 CA-09599 (AN Shah), the Eleanor B. Pillsbury Fellowship-University of Illinois Hospital (AN Shah) and the Sowell-Huggins Fellowship (J Zhang). GE Gallick is the Sowell-Huggins Professor of Cancer Biology.

PY - 2007/9

Y1 - 2007/9

N2 - Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

AB - Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

KW - Angiogenesis

KW - Metastasis

KW - Protein tyrosine kinase

KW - Src family kinase

KW - Tumor progression

KW - Tyrosine kinase inhibitors

KW - VEGF

KW - Vascular permeability

UR - https://www.scopus.com/pages/publications/34548851971

U2 - 10.1517/14728222.11.9.1207

DO - 10.1517/14728222.11.9.1207

M3 - Review article

C2 - 17845146

AN - SCOPUS:34548851971

SN - 1472-8222

VL - 11

SP - 1207

EP - 1217

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

IS - 9

ER -

Regulation of angiogenesis and vascular permeability by src family kinases: Opportunities for therapeutic treatment of solid tumors

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this